RT Journal Article
SR Electronic
T1 Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 907
OP 917
DO 10.21873/invivo.12780
VO 36
IS 2
A1 MIOKO MATSUO
A1 RYUJI YASUMATSU
A1 MUNEYUKI MASUDA
A1 SATOSHI TOH
A1 TAKAHIRO WAKASAKI
A1 KAZUKI HASHIMOTO
A1 RINA JIROMARU
A1 TOMOMI MANAKO
A1 TAKASHI NAKAGAWA
YR 2022
UL http://iv.iiarjournals.org/content/36/2/907.abstract
AB Background/Aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment. Patients and Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed. Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p<0.05). A multivariate analysis revealed that PS, irAEs, post-GPS, post-NLR, post-CAR, and post-eosinophil count were independent prognostic factors for overall survival. Conclusion: Post-treatment factors were identified as independent prognostic factors for RMHNSCC and can more accurately predict prognosis compared to nivolumab-treated RMHNSCC pre-treatment factors.